Literature DB >> 15561877

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.

Sydney M Finegold1, Denise Molitoris, Marja-Liisa Vaisanen, Yuli Song, Chengxu Liu, Mauricio Bolaños.   

Abstract

The activities of OPT-80 against 453 intestinal bacteria were compared with those of seven other drugs. OPT-80 showed good activity against most clostridia, staphylococci, and enterococci, but streptococci, aerobic and facultative gram-negative rods, anaerobic gram-negative rods, and Clostridium ramosum were resistant. Poor activity against anaerobic gram-negative rods may maintain colonization resistance.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15561877      PMCID： PMC529236          DOI： 10.1128/AAC.48.12.4898-4902.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.

Authors:  R Fekety
Journal:  Am J Gastroenterol       Date:  1997-05       Impact factor: 10.864

2.  Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study.

Authors:  E Tacconelli; M Tumbarello; K G Donati; M Bettio; T Spanu; F Leone; L A Sechi; S Zanetti; G Fadda; R Cauda
Journal:  Clin Infect Dis       Date:  2001-10-05       Impact factor: 9.079

Review 3.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors:  K Hiramatsu
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

4.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.

Authors:  T L Smith; M L Pearson; K R Wilcox; C Cruz; M V Lancaster; B Robinson-Dunn; F C Tenover; M J Zervos; J D Band; E White; W R Jarvis
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

5.  Gastrointestinal microflora studies in late-onset autism.

Authors:  Sydney M Finegold; Denise Molitoris; Yuli Song; Chengxu Liu; Marja-Liisa Vaisanen; Ellen Bolte; Maureen McTeague; Richard Sandler; Hannah Wexler; Elizabeth M Marlowe; Matthew D Collins; Paul A Lawson; Paula Summanen; Mehmet Baysallar; Thomas J Tomzynski; Erik Read; Eric Johnson; Rial Rolfe; Palwasha Nasir; Haroun Shah; David A Haake; Patricia Manning; Ajay Kaul
Journal:  Clin Infect Dis       Date:  2002-09-01       Impact factor: 9.079

6.  In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Authors:  R N Swanson; D J Hardy; N L Shipkowitz; C W Hanson; N C Ramer; P B Fernandes; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

7.  Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology.

Authors:  Ellie Hershberger; Susan Donabedian; Konstantinos Konstantinou; Marcus J Zervos
Journal:  Clin Infect Dis       Date:  2003-12-05       Impact factor: 9.079

8.  Mechanisms and implications of glycopeptide resistance in enterococci.

Authors:  E Derlot; P Courvalin
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

Review 9.  Antibiotic-associated diarrhea.

Authors:  J G Bartlett
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

10.  In vitro activity of OPT-80 against Clostridium difficile.

Authors:  Grit Ackermann; Birgit Löffler; Daniela Adler; Arne C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
View more
  47 in total

1.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

Authors:  Douglas J Biedenbach; James E Ross; Shannon D Putnam; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 3.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

4.  Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin.

Authors:  Maxime Gualtieri; Philippe Villain-Guillot; Jaqueline Latouche; Jean-Paul Leonetti; Lionel Bastide
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Authors:  Y K Shue; P S Sears; S Shangle; R B Walsh; C Lee; S L Gorbach; F Okumu; R A Preston
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

6.  In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.

Authors:  James A Karlowsky; Nancy M Laing; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

Review 7.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

8.  Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Authors:  Farah Babakhani; Jaime Seddon; Pamela Sears
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.

Authors:  Thomas J Louie; Judy Emery; Walter Krulicki; Brendan Byrne; Manuel Mah
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.